Claims for Patent: 6,054,122

Summary for Patent: 6,054,122

Title:	Supplemented and unsupplemented tissue sealants, methods of their production and use
Abstract:	This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.
Inventor(s):	MacPhee; Martin James (Gaithersburg, MD), Drohan; William Nash (Springfield, VA), Woolverton; Christoper J. (Kent, OH)
Assignee:	The American National Red Cross (Washington, DC)
Application Number:	08/479,034
Patent Claims:	1. An expanding fibrin sealant foam for treating wounded tissue in a patient comprising (i) fibrinogen, or a derivative or metabolite thereof, in an amount which forms a fibrin matrix; and (ii) an agent which causes fibrinogen to foam during application of said fibrinogen to wounded tissue. such that said fibrinogen expands to fill the wound and form a fibrin matrix that covers and adheres to said wounded tissue. 2. The expanding fibrin sealant foam of claim 1, wherein said foam further comprises at least one component selected from the group consisting of Factor XIII, thrombin or other catalyst of fibrin formation, and Ca.sup.++. 3. The expanding fibrin sealant foam of claim 1, wherein said foam further comprises at least two components selected from the group consisting of Factor XIII, thrombin or other catalyst of fibrin formation, and Ca.sup.++. 4. The expanding fibrin sealant foam of claim 1, wherein said foam further comprises Factor XIII, thrombin or other catalyst of fibrin formation and Ca.sup.++. 5. The expanding fibrin sealant foam of claim 1, wherein said foam further comprises at least one supplement selected from the group consisting of: analgesics, anesthetic, antimicrobial compounds, antibodies, anticoagulants, antifibrinolytic agents, anti-inflammatory compounds, antiproliferatives, cytokines, cytotoxins, chemotherapeutic drugs, growth factors, hormones, interferons, lipids or lipid-containing structures, polynucleotides or oligonucleotides, osteoinducers, polymers, polysaccharides, proteoglycans, polypeptides, protease inhibitors, steroids, vasoconstrictors, vasodilators, vitamins, nutritional minerals and stabilizers. 6. The expanding fibrin sealant foam of claim 5, wherein said supplement is at least one antibody and/or at least one antimicrobial compound. 7. The exlandiny fibrin sealant foam of claim 5, wherein said supplement is at least one growth factor. 8. The expanding fibrin sealant foam of claim 7, wherein said growth factor is selected from the group consisting of: fibroblast growth factors; platelet-derived growth factors; insulin-like growth factors; epidermal growth factors; transforming growth factors; cartilage-inducing factors; osteoid-inducing factors; osteogenin and other bone growth factors; bone morphogenetic growth factors; collagen growth factors; heparin-binding growth factors; cytokines; interferons; vascular endothelial growth factors: JAGGED protein and NOTCH protein. 9. The expanadig fibrin sealant foam of claim 7, wherein said foam further comprises at least one regulatory compound selected from the group consisting of inhibiting compounds and potentiating compounds wherein said inhibiting compounds inhibit agents that interfere with the ability of said growth factor to regulate or mediate cell proliferation, cell differentiation, tissue regeneration, cell attraction, wound repair and/or any cell developmental or proliferative process, while said potentiating compounds increase and/or mediate the ability of said growth factor to regulate or mediate cell proliferation, cell differentiation, tissue regeneration, cell attraction, wound repair and/or any cell developmental or proliferative process. 10. The expanding fibrin sealant foam of claim 9, wherein said regulatory compound increases and/or mediates the ability of said growth factor supplement to regulate or mediate cell proliferation, cell differentiation, tissue regeneration, cell attraction, wound repair and/or any cell developmental or proliferative process while also inhibiting agents that interfere with the ability of said growth factor to regulate or mediate cell proliferation, cell differentiation, tissue regeneration, cell attraction, wound repair and/or any cell developmental or proliferative process. 11. The expanding fibrin sealant foam of claim 7 or 9, wherein said foam further comprises at least one antibody and/or antimicrobial compound. 12. The expanding fibrin sealant foam of claim 7 or 9, wherein said foam further comprises at least one cytotoxin or cell proliferation inhibiting compound. 13. The expanding fibrin sealant foam of claim 5, wherein said supplement is at least one cytotoxin or cell proliferation inhbiting compound. 14. The expanding fibrin sealant foam of claim 13, wherein said cytotoxin or cell proliferation inhibiting compound is selected from the group consisting of alkylating agents, enzyme inhibitors, proliferation inhibitors, lytic agents, DNA or RNA synthesis inhibitors, membrane permeability modifiers, DNA intercalators, metabolites, dichloroethylsulfide derivatives, protein production inhibitors, ribosome inhibitors, inducers of apoptosis, and neurotoxins. 15. The expandixig fibrin sealant foam of claim 13, wherein said cytotoxin or cell proliferation inhibiting compound is selected from the group consisting of 5-fluorouracil, actinomycin D, adriamycin, azaribine, bleomycin, busulfan, carmustine, chlorambucil, cisplatin, cytarabine, dacarbazine, estrogen, hormone analogs, insulins, hydoxyurea, L-asparaginase, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin C, prednisolone, prednisone, procarbazine, steroids, streptozotocin, testosterone, thioguanine, thiotepa, vinblastine, vincristine, taxol, taxotere, gentainycin, carboplatin, cyclophosphamide, ifosphamide, maphosphamide, ricin, diptheria toxin or derivatives thereof, and venoms or derivatives thereof. 16. The expanding fibrin sealant foam of claim 13, wherein said further comprises at least one antibody and/or antimicrobial compound. 17. The expanding fibrin sealant foam of claim 5, wherein said supplement is released from said fibrin matrix long term. 18. the expanding fibrin sealant foam of claim 17, wherein said supplement interacts with said fibrin matrix. 19. The expanding fibrin sealant foam of claim 17, wherein said supplement is of sufficiently low solubility to permit localized, sustained-release of said supplement from said fibrin matrix. 20. The expanding fibrin sealant foam of claim 17, wherein said supplement is in solid form. 21. The expanding fibrin sealant foam of claim 17, wherein upon application said supplement is introduced in solution in a carrier, said carrier having a higher rate of diffusion or dissolution than said supplement contained therein, so that said supplement is deposited within said fibrin matrix as a solid precipitate. 22. The expanding fibrin sealant foam of claim 17, wherein the mass of said supplement exceeds the amount which is soluble in the volume of said fibrin matrix, thereby permitting localized, sustained-release of said supplement from said fibrin matrix. 23. The expanding fibrin sealant foam of claim 17, wherein upon application said supplement is introduced as an emulsion. 24. The expanding fibrin sealant foam of claim 1, wherein said foam further comprises at least one supplement selected from the group consisting of: demineralized bone matrix and bone morphogenetic proteins 1 to 8. 25. The expanding fibrin sealant foam of claim 1, wherein said foam further comprises at least one supplement selected from the group consisting of fibrin, collagen, gelatin, chitin, chitosan, NOCC-chitosan and derivatives of fibrin. collagen, gelatin, chitin, chitosan and NOCC-chitosan. 26. The expanding fibrin sealant foam of claim 1, wherein said agent which causes fibrinogen to foam is a chemical or mixture of chemicals which produces gas upon contact with a hydrating agent. 27. A method of treating wounded tissue in a patient by applying to said wound the fibrin sealant foam of any one of claims 1-10. 28. A supplemented fibrin matrix formed by applying the expanding fibrin sealant foam of claim 5. 29. The expanding fibrin sealant foam of claim 5, wherein said supplement is an anesthetic. 30. The expanding fibrin sealant foam of claim 5, wherein said supplement is an anesthetic and an antimicrobial compound. 31. The expanding fibrin sealant foam of claim 1, wherein said fibrinogen is recombinantly-produced human fibrinogen. 32. The expanding fibrin sealant foam of any one of claims 2-4, wherein said thrombin is recombinantly-produced human thrombin. 33. The expanding fibrin sealant foam of any one of claims 2-4, wherein said Factor XIII is recombinantly-produced human Factor XIII. 34. The expanding fibrin sealant foam of claim 8, wherein said growth factor is selected from the group consisting of: fibroblast growth factor-1, fibroblast growth factor-2 and fibroblast growth factor-4; platelet-derived growth factor; insulin-like growth factor-1, insulin-like growth factor-2; epidermal growth factor; transforming growth factor-.alpha.; transforming growth factor-.beta.; cartilage-inducing factor-A, cartilage-inducing factor-B; osteoid-inducing factor; osteogenin; bone morphogenetic growth factor; collagen growth factor; heparin-binding growth factor-1 and heparin-binding growth factor-2. 35. The fibrin sealant foam of claim 1, wherein said agent which causes fibrinogen to foam is a physiologically acceptable propellant. 36. The fibrin sealant foam of claim 35, wherein said propellant is selected from the group consisting of carbon dioxide, nitrogen, chlorofluorocarbons and hydrofluorocarbons. 37. The method of claim 27, wherein said fibrin foam arrests the flow of blood from bleeding vessels or tissue in said wounded tissue. 38. The method of claim 27, wherein said fibrin foam fills said wound or the body cavity containing said wound, thereby arresting hemorrhage by exerting pressure on bleeding vessels in said wounded tissue. 39. The method of claim 27, wherein said fibrin foam seals said wound to prevent the flow of fluids or gases into or out of said wound. 40. The method of claim 28, wherein said fibrin foam arrests the flow of blood from bleeding vessels in said wounded tissue. 41. The method of claim 28 wherein said fibrin foam fills said wound or the body cavity containing said wound, thereby arresting hemorrhage by exerting pressure on bleeding vessels in said wounded tissue. 42. The method of claim 28 wherein said fibrin foam seals said wound to prevent the flow of fluids or gases into or out of said wound. 43. A method of treating wounded tissue in a patient by applying to said wound the fibrin sealant foam of any one of claims 13-26 or 29-42.

Details for Patent 6,054,122

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2017-04-25